1700-29-4

Basic information

• Product Name: 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE
• Synonyms: 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE;4-Benzyloxy-3-methoxybenzyl cyanide;2-(4-(Benzyloxy)-3-Methoxyphenyl)acetonitrile;4-Benzyloxy-3-methoxybenzyl cyanide, 2-(Benzyloxy)-5-(cyanomethyl)anisole
• CAS NO: 1700-29-4
• Molecular Formula: C₁₆H₁₅NO₂
• Molecular Weight: 253.3
• Product Categories: Aromatic Nitriles
• Mol File: 1700-29-4.mol
• Article Data: 13

Chemical Properties

• Melting Point: 68-70°C
• Boiling Point: 195°C 1mm
• Flash Point: 195°C/1mm
• Appearance: /
• Density: 1.129 g/cm³
• Vapor Pressure: 5.98E-07mmHg at 25°C
• Refractive Index: 1.569
• Storage Temp.: Sealed in dry,Room Temperature
• BRN: 2702492
• CAS DataBase Reference: 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE(1700-29-4)
• EPA Substance Registry System: 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE(1700-29-4)

Safety Data

• Hazard Codes: Xi
• Statements: 22
• Safety Statements: 22-36/37
• RIDADR: 3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 1700-29-4(Hazardous Substances Data)

Usage

General Description

4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE is a chemical compound that belongs to the class of phenylacetonitriles. It is a white crystalline solid with a molecular formula of C16H15NO2 and a molecular weight of 253.3 g/mol. 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE is commonly used in the synthesis of various pharmaceuticals and agrochemicals. It is also used as an intermediate in the production of organic compounds and as a building block for the preparation of other chemical substances. 4-BENZYLOXY-3-METHOXYPHENYLACETONITRILE is known for its potential biological properties and is used in research and development for the creation of new medicinal and agricultural products.

InChI:InChI=1/C16H15NO2/c1-18-16-11-13(9-10-17)7-8-15(16)19-12-14-5-3-2-4-6-14/h2-8,11H,9,12H2,1H3

Upstream product

• 33688-50-5 1-(benzyloxy)-4-(chloromethyl)-2-methoxybenzene 
• 143-33-9 sodium cyanide 
• 13435-20-6 tetraethylammoniumcyanide 
• 121-33-5 vanillin 
• 1860-54-4 5-(4-benzyloxy-3-methoxy-benzylidene)-2-thioxo-thiazolidin-4-one 
• 100-39-0 benzyl bromide 
• 4468-59-1 4-hydroxy-3-methoxyphenylacetonitrile 
• 1700-28-3 β-(4-Benzyloxy-3-methoxy-benzyl)-α-thioxopropionsaeure 
• 100-44-7 benzyl chloride 
• 498-00-0 4-hydroxymethyl-2-methoxyphenol 
• 33693-48-0 4-benzyloxy-3-methoxybenzyl alcohol 
• 2426-87-1 3-methoxy-4-(phenylmethoxy)benzaldehyde 
• 151-50-8 potassium cyanide 
• 1860-55-5 α-(4-Benzyloxy-3-methoxy-benzyl)-α-oximinoessigsaeure 

Downstream Products

• 70303-67-2 2-(4-Benzyloxy-3-methoxy-phenyl)-2-ethyl-pentanedinitrile 
• 65341-83-5 (4-Benzyloxy-2-bromo-5-methoxy-phenyl)-acetonitrile 
• 29973-91-9 4-benzyloxy-3-methoxyphenylacetic acid 
• 13255-24-8 (3-benzyloxy-4-methoxy-phenyl)-acetic acid-(3,4-bis-benzyloxy-phenethylamide) 

Relevant articles and documents

Synthesis and biological evaluation of a D-ring-contracted analogue of lamellarin D

A D-ring contracted analogue of the strongly cytotoxic marine pyrrole alkaloid lamellarin D was synthesized and investigated for its antiproliferative action towards a wild type and a multidrug resistant (MDR) cancer cell line. The compound was found to inhibit tumor cell growth at submicromolar concentrations and showed a lower relative resistance in the MDR cell line than the antitumor drug camptothecin to which lamellarin D shows cross resistance and with which lamellarin D shares the same binding site.

AMIDE DERIVATIVES COMPRISING HETEROCYCLOALKYL RING

PROBLEM TO BE SOLVED: To provide compounds or pharmacologically acceptable salts thereof that have excellent EP300 and/or CREBBP histone acetyltransferase inhibitory activity. SOLUTION: The invention provides compounds represented by the formula (1) in the figure or pharmacologically acceptable salts thereof. (In the formula (1), ring Q1, ring Q2, ring Q3, X and L are as defined in the specification.) SELECTED DRAWING: None COPYRIGHT: (C)2020,JPO&INPIT

Facile and Divergent Synthesis of Lamellarins and Lactam-Containing Derivatives with Improved Drug Likeness and Biological Activities

With the goal to improve the aqueous solubility of lamellarins, the lactone ring in their skeleton was replaced with a lactam moiety in azalamellarins. However, the reported synthetic route produced such derivatives in very low yields. Hence, this study focused on developing an efficient simplified total synthetic scheme that could furnish both azalamellarins and the parent lamellarins from the same pyrrole ester intermediates. Subsequent comparative profiling revealed that the introduced lactone-to-lactam replacement rendered these molecules less lipophilic, whereas their cancer cytotoxicity remained equipotent to that of the parent compounds. Interestingly, their inhibitory activity was significantly enhanced towards the multifaceted GSK-3β enzyme. Our results clearly demonstrate the therapeutic potential of this promising class of marine-derived natural products and justify their further development, especially into anticancer agents.